Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Year Ending March 31, 2021

07/30/2021 | 02:00am EDT

Takeda Pharmaceutical Company Limited provided earnings guidance for the year ending March 31, 2021. For the period, the company expects revenue of ¥3,370,000 million, Operating profit of ¥488,000 million, Net profit attributable to owners of the company of ¥250,000 million or ¥159.91 basic per share.


© S&P Capital IQ 2021
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
09/23Takeda Pharmaceutical Commences Construction on Zero-Emissions Building in Singapore fo..
MT
09/23TAKEDA PHARMACEUTICAL : WFP and Takeda deepen partnership in West Africa to strengthen hea..
AQ
09/23Navicon acquired Product Portfolio from Takeda Pharmaceutical Company Limited.
CI
09/22TAKEDA PHARMACEUTICAL : Breaks Ground on its First Zero Energy Building in Singapore
PU
09/22TAKEDA PHARMACEUTICAL : WFP and Takeda deepen partnership in West Africa to strengthen hea..
AQ
09/22TAKEDA PHARMACEUTICAL : Selects Four New Partners for Annual Global Corporate Social Respo..
BU
09/21MIRUM PHARMACEUTICALS : Partners With Takeda Over Developing, Commercializing Liver Diseas..
MT
09/21TAKEDA PHARMACEUTICAL : Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Ag..
BU
09/21Mirum Pharmaceuticals, Inc and Takeda Pharmaceutical Company Limited Enter into Exclusi..
CI
09/21Mirum Inks Japan License for Maralixibat With Takeda
DJ
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Financials
Sales 2022 3 387 B 30 577 M 30 577 M
Net income 2022 253 B 2 288 M 2 288 M
Net Debt 2022 3 472 B 31 352 M 31 352 M
P/E ratio 2022 23,6x
Yield 2022 4,77%
Capitalization 5 930 B 53 563 M 53 542 M
EV / Sales 2022 2,78x
EV / Sales 2023 2,64x
Nbr of Employees 47 099
Free-Float 99,3%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | 4502 | JP3463000004 | MarketScreener
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 3 771,00 JPY
Average target price 4 844,67 JPY
Spread / Average Target 28,5%
EPS Revisions
Managers and Directors
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Norimasa Takeda Chief Accounting Officer & Corporate Controller
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED0.43%53 563
JOHNSON & JOHNSON4.44%432 675
ROCHE HOLDING AG10.16%321 605
PFIZER, INC.20.05%246 358
NOVO NORDISK A/S50.45%231 485
ELI LILLY AND COMPANY37.22%210 037